NCT03762122

Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

Terminated Phase 2 Last updated 9 November 2022

What this trial tests

Phase 2 trial testing Rogaratinib in Squamous-cell Non-small Cell Lung Cancer in 15 participants. Terminated before completion.

Timeline

25 July 2019

Primary endpoint
13 August 2021

24 August 2021

Quick facts

Lead sponsor	Swiss Cancer Institute
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	25 July 2019
Primary completion	13 August 2021
Estimated completion	24 August 2021
Sites	11 locations across Switzerland

Drugs / interventions tested

• Rogaratinib — full drug profile →

Conditions studied

• Squamous-cell Non-small Cell Lung Cancer — all drugs for Squamous-cell Non-small Cell Lung Cancer →

Sponsor

Swiss Cancer Institute

Who can join

18 and older, any sex, with Squamous-cell Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A recent investigation showed that a substantial proportion of patients with SQCLC (46%) exhibit tumor overexpression of fibroblast growth factor receptor (FGFR) messenger ribonucleic acid (mRNA) and are potentially sensitive to FGFR-targeting treatment. Rogaratinib is a novel pan-FGFR inhibitor which showed strong anti-tumor efficacy in pre-clinical models as a single agent in FGFR pathway-addicted tumor models. SQCLC patients overexpressing tumor FGFR mRNA, who will be included into this clinical trial, do not have currently any alternative systemic treatment with a proven and clinically reasonable benefit.

The objective of the trial is to determine clinical activity and safety of rogaratinib in patients with advanced SQCLC overexpressing tumor FGFR1-3 mRNA.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Angiogenic signaling pathways and anti-angiogenic therapy for cancer.
   Liu ZL, Chen HH, Zheng LL, Sun LP, et al · · 2023 · cited 808× · PMID 37169756 · DOI 10.1038/s41392-023-01460-1
2. Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures.
   Feng B, Wu J, Shen B, Jiang F, et al · · 2022 · cited 150× · PMID 35488263 · DOI 10.1186/s12935-022-02599-7
3. FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.
   De Luca A, Esposito Abate R, Rachiglio AM, Maiello MR, et al · · 2020 · cited 87× · PMID 32962091 · DOI 10.3390/ijms21186856
4. Tyrosine Kinase Receptors in Oncology.
   Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Román-Gil M, et al · · 2020 · cited 72× · PMID 33198314 · DOI 10.3390/ijms21228529
5. FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
   Levine KM, Ding K, Chen L, Oesterreich S. · · 2020 · cited 68× · PMID 32492514 · DOI 10.1016/j.pharmthera.2020.107590
6. Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer.
   Li S, de Camargo Correia GS, Wang J, Manochakian R, et al · · 2023 · cited 47× · PMID 37296863 · DOI 10.3390/cancers15112899
7. Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.
   Pacini L, Jenks AD, Lima NC, Huang PH. · · 2021 · cited 46× · PMID 34068816 · DOI 10.3390/cells10051154
8. Biological Significance and Targeting of the FGFR Axis in Cancer.
   Chioni AM, Grose RP. · · 2021 · cited 45× · PMID 34830836 · DOI 10.3390/cancers13225681